DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Imexon is an investigational drug.
There have been 8 clinical trials for Imexon. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Burkitt Lymphoma, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are AmpliMed Corporation, University of Rochester, and University of Arizona.
Recent Clinical Trials for Imexon
|Imexon for Relapsed Follicular and Aggressive Lymphomas||University of Arizona||Phase 2|
|Imexon for Relapsed Follicular and Aggressive Lymphomas||University of Rochester||Phase 2|
|A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer||AmpliMed Corporation||Phase 2|